Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HM61713 in NSCLC Patients With EGFR Mutation
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2018
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
- 23 Apr 2018 Status changed from active, no longer recruiting to completed.
- 14 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Oct 2017.
- 16 Jun 2016 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History